Top

BMC Psychiatry

Published in:

Open Access 01-12-2021 | Schizophrenia | Research

A systematic review of the effects of psychiatric medications on social cognition

Authors: Zoë Haime, Andrew J. Watson, Nadia Crellin, Louise Marston, Eileen Joyce, Joanna Moncrieff

Published in: BMC Psychiatry | Issue 1/2021

Abstract

Introduction

Social cognition is an important area of mental functioning relevant to psychiatric disorders and social functioning, that may be affected by psychiatric drug treatments. The aim of this review was to investigate the effects of medications with sedative properties, on social cognition.

Method

This systematic review included experimental and neuroimaging studies investigating drug effects on social cognition. Data quality was assessed using a modified Downs and Black checklist (Trac et al. CMAJ 188: E120-E129, 2016). The review used narrative synthesis to analyse the data.

Results

40 papers were identified for inclusion, 11 papers investigating benzodiazepine effects, and 29 investigating antipsychotic effects, on social cognition.

Narrative synthesis showed that diazepam impairs healthy volunteer’s emotion recognition, with supporting neuroimaging studies showing benzodiazepines attenuate amygdala activity. Studies of antipsychotic effects on social cognition gave variable results. However, many of these studies were in patients already taking medication, and potential practice effects were identified due to short-term follow-ups.

Conclusion

Healthy volunteer studies suggest that diazepam reduces emotional processing ability. The effects of benzodiazepines on other aspects of social cognition, as well as the effects of antipsychotics, remain unclear. Interpretations of the papers in this review were limited by variability in measures, small sample sizes, and lack of randomisation. More robust studies are necessary to evaluate the impact of these medications on social cognition.

Available only for authorised users

Ostrom T. In: Wyer Jr RS, Srull TK, editors. The sovereignity of social cognition, in Handbook of social cognition. Hillsdale: Erlbaum; 1984. p. 1–38.

Ospina LH, Nitzburg GC, Shanahan M, Perez-Rodriguez MM, Larsen E, Latifoglu A, et al. Social cognition moderates the relationship between neurocognition and community functioning in bipolar disorder. J Affect Disord. 2018;235:7–14. https://doi.org/10.1016/j.jad.2018.03.013.

Weightman MJ, Air TM, Baune BT. A review of the role of social cognition in major depressive disorder. Front Psychiatry. 2014;5:179.CrossRef

Green MF, Horan WP, Lee J. Social cognition in schizophrenia. Nat Rev Neurosci. 2015;16(10):620–31. https://doi.org/10.1038/nrn4005.CrossRefPubMed

Augoustinos M, Walker I, Donaghue N. Social cognition: an integrated introduction. 2nd ed. London: Sage; 2006.

Green MF, Penn DL, Bentall R, Carpenter WT, Gaebel W, Gur RC, et al. Social cognition in schizophrenia: an NIMH workshop on definitions, assessment, and research opportunities. Schizophr Bull. 2008;34(6):1211–20. https://doi.org/10.1093/schbul/sbm145.

Taylor SE, Fiske S. Social Cognition, from Brains to Culture. 3rd ed. London: SAGE; 2017.

Baron-Cohen S. Theory of mind in normal development and autism. Prisme. 2001;34:174–83.

Lemerise EA, Arsenio WF. An integrated model of emotion processes and cognition in social information processing. Child Dev. 2000;71(1):107–18. https://doi.org/10.1111/1467-8624.00124.CrossRefPubMed

10.

Hamilton DL, Sherman SJ. Perceiving persons and groups. Psychol Rev. 1996;103(2):336–55. https://doi.org/10.1037/0033-295X.103.2.336.CrossRefPubMed

11.

Garety PA, Freeman D. Cognitive approaches to delusions: a critical review of theories and evidence. Br J Clin Psychol. 1999;38(2):113–54. https://doi.org/10.1348/014466599162700.CrossRefPubMed

12.

Spelke ES, Bernier EP, Skerry AE. In: Banaji MR, Gelman SA, editors. Core social Cognition, in navigating the social world: what infants, children, and other species can teach us. New York: Oxford University Press; 2013.

13.

Cohen S. Social relationships and health. Am Psychol. 2004;59(8):676–84. https://doi.org/10.1037/0003-066X.59.8.676.CrossRefPubMed

14.

Hannigan B, Bartlett H, Clilverd A. Improving health and social functioning: perspectives of mental health service users. J Ment Health. 1997;6(6):613–20. https://doi.org/10.1080/09638239718473.CrossRef

15.

Penn DL, Sanna LJ, Roberts DL. Social cognition in schizophrenia: an overview. Schizophr Bull. 2008;34(3):408–11. https://doi.org/10.1093/schbul/sbn014.CrossRefPubMedPubMedCentral

16.

Kessels RPC, Waanders-Oude Elferink M, van Tilborg I. Social cognition and social functioning in patients with amnestic mild cognitive impairment or Alzheimer’s dementia. J Neuropsychol. 2020;15(2):186-203.

17.

Adenzato M, Todisco P, Ardito RB. Social cognition in anorexia nervosa: evidence of preserved theory of mind and impaired emotional functioning. PLoS One. 2012;7(8):e44414. https://doi.org/10.1371/journal.pone.0044414.CrossRefPubMedPubMedCentral

18.

Schmidt SJ, Mueller DR, Roder V. Social cognition as a mediator variable between neurocognition and functional outcome in schizophrenia: empirical review and new results by structural equation modeling. Schizophr Bull. 2011;37(Suppl 2):S41–54. https://doi.org/10.1093/schbul/sbr079.CrossRefPubMedPubMedCentral

19.

Derntl B, Habel U. Deficits in social cognition: a marker for psychiatric disorders? Eur Arch Psychiatry Clin Neurosci. 2011;261(Suppl 2):S145–9. https://doi.org/10.1007/s00406-011-0244-0.CrossRefPubMed

20.

Deakin JB, Aitken MRF, Dowson JH, Robbins TW, Sahakian BJ. Diazepam produces disinhibitory cognitive effects in male volunteers. Psychopharmacology. 2004;173(1–2):88–97. https://doi.org/10.1007/s00213-003-1695-4.CrossRefPubMed

21.

Ramaekers JG, Louwerens JW, Muntjewerff ND, Milius H, de Bie A, Rosenzweig P, et al. Psychomotor, cognitive, extrapyramidal, and affective functions of healthy volunteers during treatment with an atypical (amisulpride) and a classic (haloperidol) antipsychotic. J Clin Psychopharmacol. 1999;19(3):209–21. https://doi.org/10.1097/00004714-199906000-00003.

22.

Veselinovic T, et al. Effects of antipsychotic treatment on cognition in healthy subjects. J Psychopharmacol. 2013;27(4):374–85. https://doi.org/10.1177/0269881112466183.CrossRefPubMed

23.

Kleykamp BA, Griffiths RR, Mintzer MZ. Dose effects of triazolam and alcohol on cognitive performance in healthy volunteers. Exp Clin Psychopharmacol. 2010;18(1):1–16. https://doi.org/10.1037/a0018407.CrossRefPubMedPubMedCentral

24.

Vigen CL, et al. Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD. Am J Psychiatry. 2011;168(8):831–9. https://doi.org/10.1176/appi.ajp.2011.08121844.CrossRefPubMedPubMedCentral

25.

Keefe RS, et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Arch Gen Psychiatry. 2007;64(6):633–47. https://doi.org/10.1001/archpsyc.64.6.633.CrossRefPubMed

26.

Weickert TW, Goldberg TE, Marenco S, Bigelow LB, Egan MF, Weinberger DR. Comparison of cognitive performances during a placebo period and an atypical antipsychotic treatment period in schizophrenia: critical examination of confounds. Neuropsychopharmacology. 2003;28(8):1491–500. https://doi.org/10.1038/sj.npp.1300216.CrossRefPubMed

27.

Faber G, Smid HGOM, van Gool AR, Wiersma D, van den Bosch RJ. The effects of guided discontinuation of antipsychotics on neurocognition in first onset psychosis. Eur Psychiatry. 2012;27(4):275–80. https://doi.org/10.1016/j.eurpsy.2011.02.003.CrossRefPubMed

28.

Husa AP, Moilanen J, Murray GK, Marttila R, Haapea M, Rannikko I, et al. Lifetime antipsychotic medication and cognitive performance in schizophrenia at age 43 years in a general population birth cohort. Psychiatry Res. 2017;247:130–8. https://doi.org/10.1016/j.psychres.2016.10.085.

29.

Healy D, Farquhar G. Immediate effects of droperidol. Hum Psychopharmacol. 1998;13(2):113–20. https://doi.org/10.1002/(SICI)1099-1077(199803)13:2<113::AID-HUP958>3.0.CO;2-N.

30.

Moncrieff J. The myth of the magic antipsychotic. Ment Health Today. 2008;22:18–9.

31.

Kucharska-Pietura K, Mortimer A. Can antipsychotics improve social cognition in patients with schizophrenia? CNS Drugs. 2013;27(5):335–43. https://doi.org/10.1007/s40263-013-0047-0.CrossRefPubMedPubMedCentral

32.

Teplan M. Fundamentals of EEG measurement. Meas Sci Rev. 2002;2(2):1–11.

33.

Logothetis NK, Wandell BA. Interpreting the BOLD signal. Annu Rev Physiol. 2004;66(1):735–69. https://doi.org/10.1146/annurev.physiol.66.082602.092845.CrossRefPubMed

34.

Amodio DM, Bartholow BD, Ito TA. Tracking the dynamics of the social brain: ERP approaches for social cognitive and affective neuroscience. Soc Cogn Affect Neurosci. 2014;9(3):385–93. https://doi.org/10.1093/scan/nst177.CrossRefPubMed

35.

Redcay E, Moraczewski D. Social cognition in context: a naturalistic imaging approach. Neuroimage. 2020;216:116392. https://doi.org/10.1016/j.neuroimage.2019.116392.CrossRefPubMed

36.

Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009;62(10):1006–12. https://doi.org/10.1016/j.jclinepi.2009.06.005.CrossRef

37.

Popay J, et al. Guidance on the conduct of narrative synthesis in systematic reviews. London: Institute for health research; 2006.

38.

Nilsonne G, Tamm S, Golkar A, Sörman K, Howner K, Kristiansson M, et al. Effects of 25mg oxazepam on emotional mimicry and empathy for pain: a randomized controlled experiment. R Soc Open Sci. 2018;4(3). https://doi.org/10.1098/rsos.160607.

39.

Pringle A, Warren M, Gottwald J, Cowen PJ, Harmer CJ. Cognitive mechanisms of diazepam administration: a healthy volunteer model of emotional processing. Psychopharmacology. 2016;233(12):2221–8. https://doi.org/10.1007/s00213-016-4269-y.CrossRefPubMedPubMedCentral

40.

Murphy SE, Downham C, Cowen PJ, Harmer CJ. Direct effects of diazepam on emotional processing in healthy volunteers. Psychopharmacology. 2008;199(4):503–13. https://doi.org/10.1007/s00213-008-1082-2.CrossRefPubMedPubMedCentral

41.

Zangara A, Blair RJ, Curran HV. A comparison of the effects of a beta-adrenergic blocker and a benzodiazepine upon the recognition of human facial expressions. Psychopharmacology. 2002;163(1):36–41. https://doi.org/10.1007/s00213-002-1120-4.CrossRefPubMed

42.

Blair RJ, Curran HV. Selective impairment in the recognition of anger induced by diazepam. Psychopharmacology. 1999;147(3):335–8. https://doi.org/10.1007/s002130051177.CrossRefPubMed

43.

Del-Ben CM, et al. Effects of diazepam on BOLD activation during the processing of aversive faces. J Psychopharmacol. 2012;26(4):443–51. https://doi.org/10.1177/0269881110389092.CrossRefPubMed

44.

Coupland NJ, Singh AJ, Sustrik RA, Ting P, Blair R. Effects of diazepam on facial emotion recognition. J Psychiatry Neurosci. 2003;28(6):452–63.PubMedPubMedCentral

45.

Olofsson JK, Gospic K, Petrovic P, Ingvar M, Wiens S. Effects of oxazepam on affective perception, recognition, and event-related potentials. Psychopharmacology. 2011;215(2):301–9. https://doi.org/10.1007/s00213-010-2141-z.CrossRefPubMed

46.

Richter A, Grimm S, Northoff G. Lorazepam modulates orbitofrontal signal changes during emotional processing in catatonia. Hum Psychopharmacol. 2010;25(1):55–62. https://doi.org/10.1002/hup.1084.CrossRefPubMed

47.

Lawrence AD, Calder AJ, McGowan SW, Grasby PM. Selective disruption of the recognition of facial expressions of anger. Neuroreport. 2002;13(6):881–4. https://doi.org/10.1097/00001756-200205070-00029.CrossRefPubMed

48.

Rock PL, Goodwin GM, Wulff K, McTavish SFB, Harmer CJ. Effects of short-term quetiapine treatment on emotional processing, sleep and circadian rhythms. J Psychopharmacol. 2016;30(3):273–82. https://doi.org/10.1177/0269881115626336.CrossRefPubMed

49.

Mizrahi R, Addington J, Remington G, Kapur S. Attribution style as a factor in psychosis and symptom resolution. Schizophr Res. 2008;104(1–3):220–7. https://doi.org/10.1016/j.schres.2008.05.003.CrossRefPubMed

50.

Gaebel W, Wolwer W. Facial expression and emotional face recognition in schizophrenia and depression. Eur Arch Psychiatry Clin Neurosci. 1992;242(1):46–52. https://doi.org/10.1007/BF02190342.CrossRefPubMed

51.

Olivier MR, Killian S, Chiliza B, Asmal L, Schoeman R, Oosthuizen PP, et al. Cognitive performance during the first year of treatment in first-episode schizophrenia: a case-control study. Psychol Med. 2015;45(13):2873–83. https://doi.org/10.1017/S0033291715000860.

52.

Zhou Z, Zhu Y, Wang J, Zhu H. Risperidone improves interpersonal perception and executive function in patients with schizophrenia. Neuropsychiatr Dis Treat. 2017;13:101–7. https://doi.org/10.2147/NDT.S120843.CrossRefPubMed

53.

Lewis SF, Garver DL. Treatment and diagnostic subtype in facial affect recognition in schizophrenia. J Psychiatr Res. 1995;29(1):5–11. https://doi.org/10.1016/0022-3956(94)00033-N.CrossRefPubMed

54.

Herbener ES, Hill SK, Marvin RW, Sweeney JA. Effects of antipsychotic treatment on emotion perception deficits in first-episode schizophrenia. Am J Psychiatry. 2005;162(9):1746–8. https://doi.org/10.1176/appi.ajp.162.9.1746.CrossRefPubMed

55.

Roberts DL, Penn DL, Corrigan P, Lipkovich I, Kinon B, Black RA. Antipsychotic medication and social cue recognition in chronic schizophrenia. Psychiatry Res. 2010;178(1):46–50. https://doi.org/10.1016/j.psychres.2010.04.006.CrossRefPubMed

56.

Mizrahi R, et al. The effect of antipsychotic treatment on theory of mind. Psychol Med. 2007;37(4):595–601. https://doi.org/10.1017/S0033291706009342.CrossRefPubMed

57.

Kucharska-Pietura K, Mortimer A, Tylec A, Czernikiewicz A. Social cognition and visual perception in schizophrenia inpatients treated with first-and second-generation antipsychotic drugs. Clin Schizophr Relat Psychoses. 2012;6(1):14–20. https://doi.org/10.3371/CSRP.6.1.2.CrossRefPubMed

58.

Wolwer W, et al. Facial affect recognition in the course of schizophrenia. Eur Arch Psychiatry Clin Neurosci. 1996;246(3):165–70. https://doi.org/10.1007/BF02189118.CrossRefPubMed

59.

Gultekin G, Yuksek E, Kalelioglu T, Bas A, Ocek Bas T, Duran A. Differential effects of clozapine and risperidone on facial emotion recognition ability in patients with treatment-resistant schizophrenia. Psychiatry Clin Psychopharmacol. 2017;27(1):19–23. https://doi.org/10.1080/24750573.2017.1293242.CrossRef

60.

Maat A, Cahn W, Gijsman HJ, Hovens JE, Kahn RS, Aleman A. Open, randomized trial of the effects of aripiprazole versus risperidone on social cognition in schizophrenia. Eur Neuropsychopharmacol. 2014;24(4):575–84. https://doi.org/10.1016/j.euroneuro.2013.12.009.CrossRefPubMed

61.

Behere RV, Venkatasubramanian G, Arasappa R, Reddy N, Gangadhar BN. Effect of risperidone on emotion recognition deficits in antipsychotic-naive schizophrenia: a short-term follow-up study. Schizophr Res. 2009;113(1):72–6. https://doi.org/10.1016/j.schres.2009.05.026.CrossRefPubMed

62.

Harvey PD, et al. Improvement in social competence with short-term atypical antipsychotic treatment: a randomized, double-blind comparison of quetiapine versus risperidone for social competence, social cognition, and neuropsychological functioning. Am J Psychiatry. 2006;163(11):1918–25. https://doi.org/10.1176/ajp.2006.163.11.1918.CrossRefPubMed

63.

Shi C, Yao Shuqiao S, Xu Y, Shi J, Xu X, Zhang C, et al. Improvement in social and cognitive functioning associated with paliperidone extended-release treatment in patients with schizophrenia: a 24-week, single arm, open-label study. Neuropsychiatr Dis Treat. 2016;12:2095–104. https://doi.org/10.2147/NDT.S112542.

64.

Penn DL, Keefe RSE, Davis SM, Meyer PS, Perkins DO, Losardo D, et al. The effects of antipsychotic medications on emotion perception in patients with chronic schizophrenia in the CATIE trial. Schizophr Res. 2009;115(1):17–23. https://doi.org/10.1016/j.schres.2009.08.016.

65.

Sergi MJ, et al. Social cognition [corrected] and neurocognition: effects of risperidone, olanzapine, and haloperidol. Am J Psychiatry. 2007;164(10):1585–92. https://doi.org/10.1176/appi.ajp.2007.06091515.CrossRefPubMed

66.

Kee KS, Kern RS, Marshall BD Jr, Green MF. Risperidone versus haloperidol for perception of emotion in treatment-resistant schizophrenia: preliminary findings. Schizophr Res. 1998;31(2–3):159–65. https://doi.org/10.1016/S0920-9964(98)00026-7.CrossRefPubMed

67.

Koshikawa Y, Takekita Y, Kato M, Sakai S, Onohara A, Sunada N, et al. The comparative effects of risperidone long-acting injection and Paliperidone palmitate on social functioning in schizophrenia: a 6-month, open-label, Randomized Controlled Pilot Trial. Neuropsychobiology. 2016;73(1):35–42. https://doi.org/10.1159/000442209.

68.

Daros AR, Ruocco AC, Reilly JL, Harris MSH, Sweeney JA. Facial emotion recognition in first-episode schizophrenia and bipolar disorder with psychosis. Schizophr Res. 2014;153(1–3):32–7. https://doi.org/10.1016/j.schres.2014.01.009.CrossRefPubMedPubMedCentral

69.

Savina I, Beninger RJ. Schizophrenic patients treated with clozapine or olanzapine perform better on theory of mind tasks than those treated with risperidone or typical antipsychotic medications. Schizophr Res. 2007;94(1–3):128–38. https://doi.org/10.1016/j.schres.2007.04.010.CrossRefPubMed

70.

Fakra E, Salgado-Pineda P, Besnier N, Azorin JM, Blin O. Risperidone versus haloperidol for facial affect recognition in schizophrenia: findings from a randomised study. World J Biol Psychiatry. 2009;10(4 Pt 3):719–28. https://doi.org/10.1080/15622970701432536.CrossRefPubMed

71.

Labuschagne I, Jones R, Callaghan J, Whitehead D, Dumas EM, Say MJ, et al. Emotional face recognition deficits and medication effects in pre-manifest through stage-II Huntington's disease. Psychiatry Res. 2013;207(1–2):118–26. https://doi.org/10.1016/j.psychres.2012.09.022.

72.

Kucharska-Pietura K, Tylec A, Czernikiewicz A, Mortimer A. Attentional and emotional functioning in schizophrenia patients treated with conventional and atypical antipsychotic drugs. Med Sci Monit. 2012;18(1):CR44–9. https://doi.org/10.12659/msm.882202.CrossRefPubMedPubMedCentral

73.

Sumiyoshi T, Higuchi Y, Itoh T, Matsui M, Arai H, Suzuki M, et al. Effect of perospirone on P300 electrophysiological activity and social cognition in schizophrenia: a three-dimensional analysis with sloreta. Psychiatry Res. 2009;172(3):180–3. https://doi.org/10.1016/j.pscychresns.2008.07.005.

74.

Takahashi H, Yahata N, Koeda M, Takano A, Asai K, Suhara T, et al. Effects of dopaminergic and serotonergic manipulation on emotional processing: a pharmacological fMRI study. Neuroimage. 2005;27(4):991–1001. https://doi.org/10.1016/j.neuroimage.2005.05.039.

75.

Franken IH, Nijs I, Pepplinkhuizen L. Effects of dopaminergic modulation on electrophysiological brain response to affective stimuli. Psychopharmacology. 2008;195(4):537–46. https://doi.org/10.1007/s00213-007-0941-6.CrossRefPubMed

76.

Wesnes K, Pincock C. Practice effects on cognitive tasks: a major problem? Lancet Neurol. 2002;1(8):473. https://doi.org/10.1016/S1474-4422(02)00236-3.CrossRefPubMed

77.

Foeckler, P., V. Henning, and J. Reichelt, Mendeley. 2008: London, UK

78.

Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health. 1998;52(6):377–84. https://doi.org/10.1136/jech.52.6.377.CrossRefPubMedPubMedCentral

79.

Trac MH, McArthur E, Jandoc R, Dixon SN, Nash DM, Hackam DG, et al. Macrolide antibiotics and the risk of ventricular arrhythmia in older adults. CMAJ. 2016;188(7):E120–9. https://doi.org/10.1503/cmaj.150901.

80.

McHugh ML. Interrater reliability: the kappa statistic. Biochem Med (Zagreb). 2012;22(3):276–82. https://doi.org/10.11613/BM.2012.031.CrossRef

81.

Zurowska N, et al. Recognition of emotional facial expressions in benzodiazepine dependence and detoxification. Cogn Neuropsychiatry. 2018;23(2):74–87. https://doi.org/10.1080/13546805.2018.1426448.CrossRefPubMed

82.

Paulus MP, Feinstein JS, Castillo G, Simmons AN, Stein MB. Dose-dependent decrease of activation in bilateral amygdala and insula by lorazepam during emotion processing. Arch Gen Psychiatry. 2005;62(3):282–8. https://doi.org/10.1001/archpsyc.62.3.282.CrossRefPubMed

83.

Fujii DE, Wylie AM, Nathan JH. Neurocognition and long-term prediction of quality of life in outpatients with severe and persistent mental illness. Schizophr Res. 2004;69(1):67–73. https://doi.org/10.1016/S0920-9964(03)00122-1.CrossRefPubMed

84.

Hudson C, Chan J. Individuals with intellectual disability and mental illness: a literature review. Aust J Soc Issues. 2016;37(1):31–49. https://doi.org/10.1002/j.1839-4655.2002.tb01109.x.CrossRef

85.

Banks SJ, Eddy KT, Angstadt M, Nathan PJ, Phan KL. Amygdala-frontal connectivity during emotion regulation. Soc Cogn Affect Neurosci. 2007;2(4):303–12. https://doi.org/10.1093/scan/nsm029.CrossRefPubMedPubMedCentral

86.

Anderson KE, Marder KS. An overview of psychiatric symptoms in Huntington's disease. Curr Psychiatry Rep. 2001;3(5):379–88. https://doi.org/10.1007/s11920-996-0030-2.CrossRefPubMed

87.

McKee SA. Concurrent substance use disorders and mental illness: bridging the gap between research and treatment. Can Psychol. 2017;58(1):50–7. https://doi.org/10.1037/cap0000093.CrossRef

88.

Choi JH, Kim JH, Lee J, Green MF. Social Cognition training for individuals with schizophrenia: a review of targeted interventions. Clin Psychopharmacol Neurosci. 2009;7(2):29–38.

89.

Kurtz MM, Gagen E, Rocha NBF, Machado S, Penn DL. Comprehensive treatments for social cognitive deficits in schizophrenia: a critical review and effect-size analysis of controlled studies. Clin Psychol Rev. 2016;43:80–9. https://doi.org/10.1016/j.cpr.2015.09.003.CrossRefPubMed

Title: A systematic review of the effects of psychiatric medications on social cognition
Authors: Zoë Haime
Andrew J. Watson
Nadia Crellin
Louise Marston
Eileen Joyce
Joanna Moncrieff
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Schizophrenia
Antipsychotics
Antipsychotics
Haloperidol
Risperidone
Benzodiazepine
Diazepam
Published in: BMC Psychiatry / Issue 1/2021
Electronic ISSN: 1471-244X
DOI: https://doi.org/10.1186/s12888-021-03545-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

A systematic review of the effects of psychiatric medications on social cognition

Abstract

Introduction

Method

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Method

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2021

Sensitivity and specificity of self-reported psychiatric diagnoses amongst patients treated for opioid use disorder

Scope, quality and inclusivity of international clinical guidelines on mental health and substance abuse in relation to dual diagnosis, social and community outcomes: a systematic review

Implementation, efficacy, costs and processes of inpatient equivalent home-treatment in German mental health care (AKtiV): protocol of a mixed-method, participatory, quasi-experimental trial

Correction to: Symptoms of anxiety disorders in Iranian adolescents with hearing loss during the COVID-19 pandemic

Social cognition in individuals with 22q11.2 deletion syndrome and its link with psychopathology and social outcomes: a review

Efficient visual search for facial emotions in patients with major depression